Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in a phase 3 trial, cutting 75% of its workforce.
The US regulator has rejected Sunovion’s nebulised therapy for chronic obstructive pulmonary disease (COPD), leaving the company struggling to stay ahead of rivals.